Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Outlook

Thelansis's "Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Autosomal Dominant Polycystic Kidney Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Overview

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disorder, primarily caused by mutations in the PKD1 (~78-85%) or PKD2 (~15%) genes, which encode polycystin proteins involved in renal tubular structure and signaling. While largely inherited, ~10% of cases arise from de novo mutations.

The disease is characterized by the progressive development of multiple fluid-filled renal cysts, leading to kidney enlargement (nephromegaly), hypertension, and gradual loss of renal function. Clinical severity varies significantly, with PKD1 mutations associated with a more aggressive course and earlier progression to end-stage renal disease (ESRD).

Modern disease management focuses on identifying rapid progressors using imaging biomarkers such as height-adjusted total kidney volume (htTKV). The current standard disease-modifying therapy is tolvaptan, a vasopressin V2 receptor antagonist that reduces cyst growth and slows renal decline. However, treatment remains limited, and many patients ultimately require dialysis or transplantation.

Key Highlights

• ADPKD is a chronic, progressive rare disease with significant long-term renal and cardiovascular burden.
• In the UK, incident cases are expected to increase from ~4.4K in 2025 to ~4.9K by 2035, reflecting a low growth rate (~1% CAGR).

Market Overview

• The ADPKD market in Germany is projected to grow from ~$130M in 2025 to ~$225M by 2035, reflecting a CAGR of ~5-6%.
• Current treatment landscape is limited, with Tolvaptan as the only widely adopted disease-modifying therapy

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Regulus Therapeutics Inc.
• AbbVie
• AstraZeneca
• Jemincare
• Rege Nephro Co., Ltd.
• PYC Therapeutics
• Vertex Pharmaceuticals
• Otsuka Pharmaceutical
• XORTX Therapeutics
• Poxel SA
• Calico Life Sciences
• AceLink Therapeutics
• PYC Therapeutics